[go: up one dir, main page]

ES2096685T3 - Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer. - Google Patents

Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer.

Info

Publication number
ES2096685T3
ES2096685T3 ES92113812T ES92113812T ES2096685T3 ES 2096685 T3 ES2096685 T3 ES 2096685T3 ES 92113812 T ES92113812 T ES 92113812T ES 92113812 T ES92113812 T ES 92113812T ES 2096685 T3 ES2096685 T3 ES 2096685T3
Authority
ES
Spain
Prior art keywords
group
represent
different
same
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92113812T
Other languages
English (en)
Inventor
Lan Bo Cen
Tadao Shishido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Holdings Corp
Dana Farber Cancer Institute Inc
Original Assignee
Fuji Photo Film Co Ltd
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Photo Film Co Ltd, Dana Farber Cancer Institute Inc filed Critical Fuji Photo Film Co Ltd
Application granted granted Critical
Publication of ES2096685T3 publication Critical patent/ES2096685T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
  • Paper (AREA)
  • Gas Separation By Absorption (AREA)

Abstract

SE PRESENTA UN COMPUESTO FARMACEUTICO PARA EL TRATAMIENTO DEL CANCER QUE COMPRENDE: A) UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE AL MENOS UN COMPUESTO SELECCIONADO ENTRE EL GRUPO QUE CONSTA DE COMPUESTOS REPRESENTADOS POR LA FORMULA GENERAL (I) EN LA QUE X1 Y X2, QUE PUEDEN SER IGUALES O DIFERENTES, REPRESENTAN CADA UNA O, S, SE, -CH = CH-, LA FORMULA SIGUIENTE, O LA FORMULA SIGUIENTE, Y1 REPRESENTA O, S, SE O LA FORMULA SIGUIENTE R1 Y R3, QUE PUEDEN SER IGUALES O DIFERENTES REPRESENTAN CADA UNA UN GRUPO ALQUIL; R2 REPRESENTA UN GRUPO ALQUIL, UN GRUPO ARIL O UN GRUPO HETEROCICLICO; Z1 Y Z2, QUE PUEDEN SER IGUALES O DIFERENTES, REPRESENTAN CADA UNA UN GRUPO ATOMICO NECESARIO PARA FORMAR UN ANILLO DE 5 O 6 MIEMBROS; L1 REPRESENTA UN GRUPO METINO O L1 Y L3 PUEDEN COMBINARSE Y FORMAR UN ANILLO DE 5 O 6 MIEMBROS; R4 O R5, QUE PUEDEN SER IGUALES O DIFERENTES REPRESENTAN CADA UNA UN GRUPO ALQUIL; R6 Y R7, QUE PUEDEN SER IGUALES O DIFERENTES REPRESENTAN CADA UNA UN GRUPO ALQUIL O UN GRUPO ARIL; Q REPRESENTA UN ANION FARMACEUTICAMENTE ACEPTABLE; L REPRESENTA 1 O 2; M Y N, CADA UNA PUEDE SER LO MISMO O DIFERENTES, REPRESENTAN CADA 0 O 1; B) UN PORTADOR O DILUYENTE FARMACEUTICAMENTE ACEPTABLE.
ES92113812T 1991-08-13 1992-08-13 Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer. Expired - Lifetime ES2096685T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74413091A 1991-08-13 1991-08-13

Publications (1)

Publication Number Publication Date
ES2096685T3 true ES2096685T3 (es) 1997-03-16

Family

ID=24991548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92113812T Expired - Lifetime ES2096685T3 (es) 1991-08-13 1992-08-13 Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer.

Country Status (15)

Country Link
US (1) US5360803A (es)
EP (1) EP0527494B1 (es)
JP (1) JP2567328B2 (es)
CN (1) CN1071834A (es)
AT (1) ATE144897T1 (es)
AU (1) AU649865B2 (es)
CA (1) CA2075750C (es)
DE (1) DE69215035T2 (es)
DK (1) DK0527494T3 (es)
ES (1) ES2096685T3 (es)
FI (1) FI923604A7 (es)
GR (1) GR3021865T3 (es)
HU (1) HUT64224A (es)
NO (1) NO923126L (es)
ZA (1) ZA926004B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599825A (en) * 1994-07-21 1997-02-04 Fuji Photo Film Co., Ltd. Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same
JPH10506878A (ja) * 1994-07-21 1998-07-07 富士写真フイルム株式会社 水溶性メチン化合物及び該化合物を含有する癌治療用医薬組成物
JPH0921985A (ja) * 1995-07-07 1997-01-21 Nec Corp マッハツェンダー変調器及びその製造方法
ATE253908T1 (de) 1995-08-16 2003-11-15 Huntington Medical Res Inst Rhodamin 123 zusammensetzungen für behandlung von prostatakrebs
US7329741B2 (en) * 1996-06-05 2008-02-12 Chiron Corporation Polynucleotides that hybridize to DP-75 and their use
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10032290C2 (de) * 2000-07-03 2002-05-08 Roche Diagnostics Gmbh Adsorptionsmittelhaltige Kontrollflüssigkeit
JP2003034641A (ja) * 2001-07-19 2003-02-07 Japan Science & Technology Corp ロダシアニン系色素化合物を含有する抗マラリア剤
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
JP2004331545A (ja) * 2003-05-06 2004-11-25 Japan Science & Technology Agency 抗リーシュマニア剤
FR2874319B1 (fr) * 2004-08-19 2008-05-16 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant direct methinique contenant un motif benzoselenazolium
JP4553355B2 (ja) 2004-10-04 2010-09-29 富士フイルム株式会社 トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物
US20060099712A1 (en) * 2004-11-08 2006-05-11 Eastman Kodak Company Correlation of anti-cancer activity of dyes with redox potentials
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
GB0603455D0 (en) * 2006-02-21 2006-04-05 Cancer Rec Tech Ltd Therapeutic compounds
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
US9642843B2 (en) 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
CN104177312B (zh) * 2013-05-27 2018-02-13 黄英武 一种含硒化合物及其医药用途
WO2016112394A1 (en) * 2015-01-09 2016-07-14 The Regents Of The University Of California Oxathiazole thiazolium hsp 70 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2536986A (en) * 1951-01-02 Thiazolone cyan
GB487051A (en) * 1936-11-14 1938-06-14 John David Kendall Improvements in or relating to dyestuffs
GB489335A (en) * 1937-01-22 1938-07-22 Douglas James Fry Improvements in or relating to the manufacture and use of dyestuffs suitable for sensitising photographic emulsions
US2454629A (en) * 1940-01-27 1948-11-23 Eastman Kodak Co Polymethine dyes
BE485785A (es) * 1947-11-18
BE571507A (es) * 1957-09-30
DE1493524A1 (de) * 1962-08-17 1969-06-04 Ciba Geigy Aminosaeuren
JPS53144727A (en) * 1977-05-24 1978-12-16 Konishiroku Photo Ind Co Ltd Photographic product
JPS5569513A (en) * 1978-11-20 1980-05-26 Takeda Chem Ind Ltd Anti-tumor agent
JPS54151133A (en) * 1978-05-17 1979-11-28 Takeda Chem Ind Ltd Antitumorigenic agent
JPS55100318A (en) * 1979-01-26 1980-07-31 Takeda Chem Ind Ltd Antitumorigenic agent
DE2919447A1 (de) * 1978-05-17 1979-11-22 Takeda Chemical Industries Ltd Tumorhemmendes mittel
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
JPH0652210B2 (ja) * 1987-08-26 1994-07-06 宣行 杉村 アキユムレ−タのガス封入圧力測定方法
JP2824917B2 (ja) * 1989-08-30 1998-11-18 株式会社林原生物化学研究所 抗腫瘍剤

Also Published As

Publication number Publication date
JP2567328B2 (ja) 1996-12-25
HU9202609D0 (en) 1992-10-28
JPH06172330A (ja) 1994-06-21
ATE144897T1 (de) 1996-11-15
EP0527494B1 (en) 1996-11-06
FI923604A7 (fi) 1993-02-14
CN1071834A (zh) 1993-05-12
DE69215035D1 (de) 1996-12-12
CA2075750A1 (en) 1993-02-14
NO923126D0 (no) 1992-08-11
FI923604A0 (fi) 1992-08-12
HUT64224A (en) 1993-12-28
US5360803A (en) 1994-11-01
NO923126L (no) 1993-02-15
GR3021865T3 (en) 1997-03-31
CA2075750C (en) 1998-02-24
DE69215035T2 (de) 1997-04-03
ZA926004B (en) 1993-03-02
AU2097492A (en) 1993-02-25
DK0527494T3 (da) 1996-11-25
EP0527494A1 (en) 1993-02-17
AU649865B2 (en) 1994-06-02

Similar Documents

Publication Publication Date Title
ES2096685T3 (es) Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer.
ES2067456T3 (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES8304994A1 (es) "procedimiento para preparar nuevos compuestos de cefem".
ES2167375T3 (es) Derivados flavonoides y bioflavonoides, sus composiciones farmaceuticas, su actividad ansiolitica.
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
ES2061462T3 (es) Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES8602022A1 (es) Un procedimiento para preparar un derivado de 4'-dimetil-4-epipodofilotoxina
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES379735A1 (es) Procedimiento para la preparacion de nuevos 1 - fenoxi-2- hidroxi-3-sec-alcohilaminopropanos racemicos u opticamente activos.
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
GR1001068B (el) Νέον παράγωγον 5Η-βενζοδιαζεπίνης, φαρμακευτικαί συν?έσεις περιέχουσαι τούτο, και μέ?οδος δια την παρασκευήν αυτών.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
GB1268587A (en) Phloramine derivatives
ES367521A1 (es) Un procedimiento para la preparacion de benzotiadiazoles.
GB1398687A (en) Substituted oxazolidinones and pharmaceutical uses thereof
GB1044964A (en) New aminoketones
ES430676A1 (es) Procedimiento para la preparacion de 1,2,4-tiadiazolo- (2,3-a) bencimidazoles-2-sustituidos.
MX9203068A (es) Compuestos activirales oralmente activos.
UY28119A1 (es) Nuevos derivados que contienen fosforo
ES376793A2 (es) Procedimiento de preparacion de nuevas amidas sustituidas en el nitrogeno y sus aminas correspondientes.
GB1371757A (en) Substituted aminoquinolizinium bromides their preparation and compositions thereof
FR2451380A1 (fr) Nouveaux derives du dithiepinno (1,4) (2,3-c) pyrrole, leur preparation et les medicaments qui les contiennent
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527494

Country of ref document: ES